Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

Gilead Profits Triple in Third Quarter, Revenue Up 50% Over Last Year; Viread Sales Decline

October 30, 2003

Profits for antiretroviral drug manufacturer Gilead Sciences more than tripled in the third quarter and revenue is up by 50%, compared with the same period last year, the San Francisco Chronicle reports (Tansey, San Francisco Chronicle, 10/29). Gilead, which manufactures Viread -- the fifth best-selling antiretroviral drug -- in July launched a second antiretroviral drug, Emtriva, and is developing a once-daily combination pill to compete with industry leader GlaxoSmithKline's top-selling Combivir (Kaiser Daily HIV/AIDS Report, 7/31). The financial results fell short of analysts' predictions, as third quarter revenue was $38 million less than second quarter revenue. Sales of Viread dropped during the third quarter due to wholesalers' use of overstock supplies of the drug that were purchased in the second quarter before a price increase. According to Gilead CFO John Milligan, the company is still on track to double the $226 million in revenue it brought in last year (San Francisco Chronicle, 10/29).

Back to other news for October 30, 2003


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2003 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More HIV News

Tools
 

Advertisement